There are 3 parts to the experience. First, students are given an extensive list of opportunities to learn about children with developmental disabilities or psychiatric disorders, or both, and also to learn about the various professionals in the multidisciplinary teams who work with these children. They are asked to take advantage of as many of these opportunities as possible and to keep a diary of their experience. In weekly meetings with the coordinator, the diaries are reviewed to ensure that students are engaged in a broad experience. The second requirement is a weekly case presentation. Students interview a child, review the file, and speak to other involved professionals. Over the course of the summer, students are expected to present 1 case from each residential clinical unit, so that by the end of the experience they have personally seen a range of problems. The final requirement is that students individually or collectively present a topic of interest at medical rounds or another suitable formal occasion. The students have an opportunity to write up a case under the direction of a medical geneticist and to do an original research project, medical peer assessment, or program evaluation project. This generally forms the basis of their presentation.
To date, of the participating students who have entered or submitted applications to enter postgraduate training (n = 10), 5 have enrolled in family medicine, and 5 have enrolled in psychiatry or pediatrics. (By contrast, when our program focused upon service delivery, there was no pattern to the summer students' postgraduate training choice.) The students choosing family medicine are interested in rural practice and have indicated in interview that they will need more training in these areas than is available in the basic curriculum. We continue to follow up on the summer students who have not yet declared their postgraduate training choice.
A Case of Paroxetine-Induced Galactorrhea

Dear Editor:
We report a case of galactorrhea in a 24-year-old woman (Ms N) voluntarily admitted for depression and anxiety. Paxil 10 mg taken orally once daily was prescribed, and on treatment day 5, Ms N developed galactorrhea (the nonpuerperal discharge of milk-containing fluid from the breast). This patient had no history of galactorrhea. She first noticed the discharge on the night of treatment day 5 and described it as grey-creamy (right nipple) and white-creamy (left nipple). The volume was significant enough that discharge dripped down her abdomen and flanks. She did not notice any bloody, greenish, or foul-smelling discharge. The medication was discontinued the next morning, and the discharge ceased that night.
In our approach to this patient, we sought to eliminate the most likely causes of galactorrhea. Hypothyroidism results in increased levels of thyrotropin-releasing hormone, which increases prolactin secretion. Kidneys clear prolactin, and thus, kidney disease may cause secondary hyperprolactinemia. During pregnancy, and for up to 2 years after cessation of breast-feeding, galactorrhea may be a normal finding. Because Ms N's routine admission measurements of urea, creatinine, thyroid-stimulating hormone, and beta human chorionic gonadotropin (b-HCG) were all normal, we were able to eliminate underlying kidney disease, hypothyroidism, or pregnancy as possible causes of galactorrhea.
Serum prolactin measurements taken the day that galactorrhea began and 3 days after it subsided were both within normal range. Thus, we did not observe a drugrelated increase in prolactin, and we could reassure the patient that she did not have a pituitary adenoma. When evaluating prolactin measurements in cases of galactorrhea, it must be remembered that prolactin is necessary but not sufficient to initiate lactation, and milk production may continue in the presence of normal basal plasma prolactin levels.
Clinicians should be aware of the possibility that selective serotonin reuptake inhibitors (SSRIs) can induce galactorrhea. This case report can be added to others (1,2), as well as to the manufacturer's databases (3) . The approach to patients should comprise discontinuation of the implicated SSRI, careful documentation of the galactorrhea, and documentation of recent menstrual history. Pregnancy testing and assessment of thyroid status should be done where menstrual history is equivocal or hypothyroidism is a possibility. Assessing prolactin level is likely to be low yield; it should be undertaken where clinically indicated or where there is significant patient anxiety. In cases of nonresolving galactorrhea, clinicians should direct their attention to neoplastic, structural, metabolic, and other causes, as described in Pena and Rosenfeld's recent comprehensive review (4). Canciel and others (1) add their study of Positive and Negative Syndrome Scale (PANSS)-rated symptoms of schizophrenia to the growing literature indicating that 5 symptom factors are necessary to account for symptoms of the disorder. They note many similarities in the items contained in each factor across studies but also allude to several differences that may be related to the study sample's clinical characteristics. Other possible reasons for differences in factor composition may be related to sample size and to the limitations of the principalcomponent method. Indeed, principalcomponent factor analysis is recognized as an exploratory method. We wish to bring attention to our large-scale, multicentre study of the PANSS factor structure. In it, we use the more rigorous method of confirmatory factor analysis (2) . In a sample of 1233 subjects with schizophrenia, we found that groups varying widely in age, chronicity, and illness phase did not significantly differ in their symptom structure. We identified a 5-factor structural model of the PANSS that met statistical criteria for good model fit. The criterion of good fit is an index of the degree of correspondence between the order in sample data and in the proposed model. Our model used 25 of the 30 PANSS items, organized into 5 factors: negative, positive, activation, dysphoric mood, and autistic preoccupation. Although identification of a good-fit model establishes the model's internal consistency, validity studies are necessary to demonstrate model utility. The model's discriminant validity has been demonstrated in a study of sex differences in the relation of homelessness to symptom severity (3), in a study of symptom differences between familial and deficit-syndrome schizophrenia (4), and in a study of the association between symptoms and cognitive-perceptual deficits in schizophrenia (5 
Olanzapine-Induced Hair Loss
Dear Editor:
Olanzapine is a thienobenzodiazepine atypical neuroleptic that is generally considered safe and well tolerated, compared with typical neuroleptics. However, we wish to inform clinicians of a potential toxicity associated with its use; that is, hair loss.
A 41-year-old Asian woman was admitted to hospital with a 5-year history of bizarre behaviour and erotomanic and persecutory delusions. She believed that her ex-employer was pursuing her and harassing her with messages sent via television and radio because she refused to engage in a relationship. She also believed that he had bribed her coworkers and tenants with 1 million dollars to harass her and cause water damage to her rental property.
Olanzapine (Zyprexa Zydis) 5 mg daily was initiated in hospital, and the dosage was increased to 15 mg daily over the subsequent 4 weeks. Within 2 weeks of starting olanzapine, at 7.5 to 10 mg daily, she reported gradually increasing hair loss. The hair loss accelerated when the daily dosage was increased to 15 mg. She complained of losing a handful of hair after washing or brushing it, and often found her pillow and bed sheet covered with hair in the morning. Although there was no hair count, the hair loss was obviously distressing her and was witnessed by the treatment team.
The patient continued to express delusional beliefs, and we suspected noncompliance when nursing staff noted the patient vigorously brushing her tongue shortly after taking the Zydis wafer. This was confirmed when her serum olanzapine concentration was found to be 35 nmol/L (at 10 mg taken orally daily, the average level is reported to be 74 nmol/L [1] ). Because the patient did not improve and was distressed by the side effect, we switched olanzapine to risperidone over a 1-week period. As the olanzapine dosage was reduced with the addition of risperidone, the patient reported decreased hair loss. Noncompliance to oral medications remained a problem, and she was eventually switched to flupenthixol depot, with no further complaint of hair loss. The patient was not taking any other medications prior to admission, and olanzapine was the only medication she was taking during the period of hair loss. She was otherwise healthy and had no concurrent
